In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 4 SUPPL. S1, 2000, Pages 47-49

  Mortensen, Joel E ^a   Rodgers, Gail L ^a  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; GEMIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; DRUG EFFICACY; DRUG POTENCY; HUMAN; PERTUSSIS;

ANTI-INFECTIVE AGENTS; BORDETELLA; BORDETELLA PERTUSSIS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES;

EID: 0034110572     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bass, J. W. (1986). Erythromycin for treatment and prevention of pertussis. Pediatric Infectious Disease 5, 154-7.
2. Appleman, M. E., Hadfield, T. L., Gaines, J. K. & Winn, R. E. (1987). Susceptibility of Bordetella pertussis to five quinolone antimicrobic drugs. Diagnostic Microbiology and Infectious Disease 8, 131-3.
3. Bannatyne, R. M. & Cheung, R. (1982). Antimicrobial susceptibility of Bordetella pertussis strains isolated from 1960 to 1981. Antimicrobial Agents and Chemotherapy 21, 666-7.
4. Hoppe, J. E. & Eichhorn, A. (1989). Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis. European Journal of Clinical Microbiology and Infectious Diseases 8, 653-4.
5. Hoppe, J. E. & Simon, C. G. (1990). In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to seven fluoroquinolones. Antimicrobial Agents and Chemotherapy 34, 2287-8.
6. Hoppe, J. E., Dalhoff, A. & Pfrunder, D. (1998). In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin. Antimicrobial Agents and Chemotherapy 42, 1868.
7. Kurzyinski, T. A., Boehm, D. M., Rott-Petri, J. A., Schell, R. F. & Allison, P. E. (1988). Antimicrobial susceptibilities of Bordetella species isolated in a Multicenter Pertussis Surveillance Project. Antimicrobial Agents and Chemotherapy 32, 137-40.
8. Lewis, K., Saubolle, M. A., Tenover, F. C., Rudinsky, M. F., Barbour, S. D. & Cherry, J. D. (1995). Pertussis caused by an erythromycin resistant strain of Bordetella pertussis. Pediatric Infectious Disease Journal 14, 338-91.
9. Gerding, D. N. & Hitt, J. A. (1989). Tissue penetration of the new quinolones in humans. Reviews of Infectious Diseases 11, Suppl. 5, S1046-57.
10. Hoppe, J. E. & Haug, A. (1988). Antimicrobial susceptibility of Bordetella pertussis (Part I). Infection 16, 126-30.
11. Mortensen, J. E., Rhoads, S. M., Blecker-Shelly, D. & Rodgers, G. L. (1998). A laboratory method for the in vitro susceptibility testing of Bordetella pertussis. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract D-039, p. 138. American Society for Microbiology, Washington, DC.
12. Mink, C. M., Cherry, J. D., Christenson, P., Lewis, K., Pineda, E., Shlian, D. et al. (1992). A search for Bordetella pertussis infection in university students. Clinical Infectious Diseases 14, 464-71.
13. Redmond, A. O. (1997). Risk-benefit experience of ciprofloxacin use in pediatric patients in the United Kingdom. Pediatric Infectious Disease Journal 16, 147-9.
14. Hampel, B., Hullmann, R. & Schmidt, H. (1997). Ciprofloxacin in pediatrics: worldwide clinical experience based compassionate use - safety report. Pediatric Infectious Disease Journal 16, 127-9.